ProCE Banner Activity

ECOG-ACRIN EA4151: Phase III Trial of Autologous Hematopoietic Cell Transplantation in MRD-Negative Patients With Mantle Cell Lymphoma in First Complete Remission

Conference Coverage
Slideset

In the phase III ECOG-ACRIN EA4151 trial, patients with mantle cell lymphoma in first complete remission with undetectable measurable residual disease did not benefit from autologous hematopoietic cell transplantation after induction therapy.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation